Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...

Drugs prescribed for weight loss, such as Mounjaro, Ozempic, Wegovy, and Zepbound, have been popular, expensive, and in short supply. To meet the demand, health providers like Hims & Hers had ...

Compounded versions of popular weight-loss drugs attracted telehealth companies that marketed services to connect patients ...

Hims & Hers shares surged in May after the company ... The FDA said in a statement late Wednesday that Eli Lilly's supply of Mounjaro, which is used to treat diabetes, and weight-loss drug ...

Shares of Hims & Hers Health (HIMS) sank Thursday after the Food and Drug Administration (FDA) said Eli Lilly’s (LLY) popular weight-loss treatments, Mounjaro and Zepbound, were no longer on its ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...

Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...

Shares of Hims & Hers Health fell almost 10% today following ... This means that drugs like Eli Lilly’s Mounjaro, which is used to treat diabetes, and Zepbound, which is used for weight loss ...